We agree that a single ALT measure will not accurately predict NASH or fibrosis, but rather we show that in patients with both histologic disease and an elevated ALT > 60, the change in mean ALT over time is a reasonable biomarker of improved histology. The gene discussed is GPT; the disease is metabolic dysfunction-associated steatohepatitis.